Wave sets Research Day for November 4: Wave Life Sciences stock is valued at USD 624.6 million

Published on 10/20/2026 at 14:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Wave Life Sciences stock costs EUR 2.85 on October 20, 2026. Revenue for the second quarter was USD 2.27 million versus USD 7.45 million expected.

Upcoming company events

On October 19, 2026, Wave Life Sciences announced a November 4, 2026 Research Day.
Revenue for the second quarter was USD 2.27 million versus USD 7.45 million expected.
Wave Life Sciences stock was trading at EUR 2.85 at 2:12 p.m. CEST on October 20, 2026, at Lang & Schwarz.
The Chardan conference panel is scheduled for October 20, 2026, at 9:45 a.m. ET.

WVE, US94352A1043, Illustration mit AI erstellt.

Wave Life Sciences (ISIN US94352A1043) announced on October 19, 2026, that it will host a virtual Research Day on November 4 at 9:30 a.m. ET. According to GlobeNewswire, the event will present new data on Wave's RNA medicines platform and its RNA interference, RNA editing, and bifunctional approaches.

Research Day brings a date

The November event gives investors a defined point for pipeline updates across obesity, alpha-1 antitrypsin deficiency, and PNPLA3 I148M liver disease. The company also plans to feature hepatologist Arun J. Sanyal on RNA editing for PNPLA3 I148M disease, according to GlobeNewswire.

What does the two-year trial mean?

Wave's WVE-006 program moved closer to a registrational path on October 1, 2026, after the company said the FDA supported a single two-year trial with a one-year interim analysis. The same release said Wave was on track to share data from the 600 milligram monthly multidose cohort in the fourth quarter of 2026, according to GlobeNewswire. That timeline links the next major clinical catalyst to both the interim review and the fourth-quarter data update.

Three milestones frame the pipeline

On September 23, 2026, Wave initiated a Phase 2a combination trial of WVE-007 with tirzepatide for obesity, as GlobeNewswire reported. On October 1, 2026, the FDA feedback supported the two-year WVE-006 pathway. The current event was announced on October 19, 2026, when Wave scheduled the November 4 Research Day.

The next two investor dates

Wave chief executive Paul Bolno was scheduled to join a Chardan Healthcare Conference panel on October 20, 2026, at 9:45 a.m. ET, according to GlobeNewswire. The next scheduled event is the Research Day on November 4, 2026, at 9:30 a.m. ET.

Revenue remains a valuation counterweight

For the quarter ended June 30, 2026, Wave reported revenue of USD 2.27 million and a GAAP net loss of USD 69.36 million. MarketBeat said revenue was below the USD 7.45 million consensus estimate and adjusted earnings per share missed the USD 0.30 estimate by USD 0.04. The figures leave clinical progress and financial runway as the central balance for the upcoming events.

Stock value and investor context

Wave Life Sciences has a USD 624.6 million market capitalization as of October 19, 2026, while its Nasdaq 52-week range was USD 3.04 to USD 21.73. The primary listing is Nasdaq under ticker WVE, and the company operates in biotechnology within the healthcare sector.

Wave Life Sciences was trading at EUR 2.85 at Lang & Schwarz on October 20, 2026 at 2:12 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Wave Life Sciences stock.